CHAPTER 3.1.21.

TRYPANOSOMA EVANSI INFECTION (SURRA)

SUMMARY

Definition of the disease: Trypanosoma evansi *causes a trypanosomosis known as 'surra'. It affects a large number of wild and domesticated animal species in Africa, Asia, and Central and South America. The principal host species varies geographically, but camels, horses, buffalos and cattle are particularly affected, although other animals, including wildlife, are also susceptible. It is an arthropod-borne disease; several species of haematophagous flies, including* Tabanids *and* Stomoxes, *are implicated in transferring infection from host to host, acting as mechanical vectors. In Brazil, vampire bats are also implicated in a unique type of biological transmission.*

Description of the disease: *The general clinical signs of* T. evansi *infections: pyrexia directly associated with parasitaemia together with a progressive anaemia, loss of condition and lassitude are not sufficiently pathognomonic for diagnosis. Recurrent episodes of fever and parasitaemia occur during the course of the disease. Oedema, particularly of the lower parts of the body, urticarial plaques and petechial haemorrhages of the serous membranes are sometimes observed in horses. Abortions have been reported in buffalos and camels. Nervous signs are common in horses. The disease causes immunodeficiencies that may be of high impact when interfering with other diseases or vaccination campaigns (*foot and mouth disease and haemorrhagic septicaemia for example*).*

Identification of the agent: *The general clinical signs of* T. evansi *infection are not sufficiently pathognomonic for diagnosis. Laboratory methods for detecting the parasite are required. In early infection or acute cases, when the parasitaemia is high, examination of wet blood films, stained blood smears or lymph node materials might reveal the trypanosomes. In more chronic cases, or more generally when the parasitaemia is low, the examination of thick blood smears, as well as methods of parasite concentration and the inoculation of laboratory rodents are required. In apparently healthy carriers (*animals without clinical signs*), parasites are rarely observed and mouse inoculation gives the best results. Several primer pairs targeting the subgenus (*Trypanozoon*) or the species-specific (*T. evansi) parasitic DNA sequences are available for diagnosis by polymerase chain reaction (*PCR*). PCR is more sensitive than parasitological examination, but it may give false-negative results when the parasitaemia is very low; in these cases, suspicion of potential carriers can only be confirmed by serological examination.*

Serological tests: *Infection gives rise to specific antibody responses and a variety of antibody detection tests have been introduced for laboratory and field use. Some have been partially validated, but await large-scale evaluation and standardisation. The most relevant are immunofluorescence test (*IFAT*), enzyme linked immunosorbent assays (*ELISA*) and card agglutination test (*CATT/T. evansi). For field use, only CATT/T. evansi can be applied. Pen side tests are currently unavailable. Estimates of predictive values indicate that ELISA for detecting IgG is more likely to classify correctly uninfected animals, while the CATT is more likely to classify correctly truly infected animals. ELISA would thus be suitable for verifying the disease-free status of animals prior to movement or during quarantine. CATT can be used to target individual animals for treatment with trypanocidal drugs. For declaring a disease-free status, serial testing – CATT and ELISA followed by re-testing of suspect samples – is recommended, preferably completed by PCR. In areas where* T. cruzi, T. equiperdum *or tsetse-transmitted trypanosomes occur, cross-reactions may occur with any serological test employed.*

Requirements for vaccines: *No vaccines are available for the disease.*

A. INTRODUCTION

Infection with *Trypanosoma evansi* causes a disease named *surra* in India and, amongst others, *El Debab*, *El Gafar,* Tabourit or MBori in North Africa, *Mal de Caderas* or *Murrina* in Latin America. The clinical signs of surra are indicative but are not sufficiently pathognomonic, thus, diagnosis must be confirmed by laboratory methods (Dia *et al.,* 1997a). The disease in susceptible animals, including camels (dromedary and bactrian), horses, buffalo, cattle and pigs is manifested by pyrexia, directly associated with parasitaemia, together with a progressive anaemia, loss of condition and lassitude. Such recurrent episodes lead to intermittent fever (as high as 44°C in horses [Gill, 1977]) and parasitaemia during the course of the disease. Oedema, particularly of the lower parts of the body, rough coat in camels, urticarial plaques and petechial haemorrhages of the serous membranes are sometimes observed. In advanced cases, parasites invade the central nervous system (CNS), which can lead to nervous signs (progressive paralysis of the hind quarters and, exceptionally, paraplegia), especially in horses, but also in other host species before complete recumbency and death. Abortions have been reported in buffalos and camels (Gutierrez *et al.*, 2005; Lohr *et al.,* 1986) and there are indications that the disease causes immunodeficiency (Dargantes *et al.,* 2005b; Onah *et al.,* 1998).

There is considerable variation in the pathogenicity of different strains and the susceptibility of different host species. The disease may manifest as an acute or chronic form, and in the latter case may persist for several months, possibly years. The disease is often rapidly fatal in camels and horses, but may also be fatal in buffalo, cattle, llamas and dogs, however these host species may develop mild or subclinical infections. Wild animals such as deer, capybara and coati can become infected and ill (including death), but they may also constitute a reservoir. Animals subjected to stress – malnutrition, pregnancy, work – are more susceptible to disease.

Biologically *T. evansi* is very similar to *T. equiperdum*, the causative agent of dourine (Brun *et al.,* 1998; Claes *et al.*, 2003), and morphologically resembles the slender forms of the tsetse-transmitted species, *T. brucei brucei, T. b. gambiense* and *T.b. rhodesiense.* Most of the molecular characterisations indicate that various strains of *T. evansi* isolated from Asia, Africa and South America are very homogeneous and may have a single origin (Ventura *et al.,* 2002), but other works suggest that *T. evansi* could have emerged from *T. brucei* in several instances (Jensen *et al.,* 2008; Lai *et al.,* 2008) Molecular characterisation using random amplified polymorphic DNA techniques and endonuclease fingerprinting showed that isolates of *T. evansi* and *T. equiperdum* formed a closely homogeneous group. The difficulties in differentiating *T. equiperdum* from the other *Trypanozoon* spp. have been stressed (Claes *et al.*, 2005; Zablotskij *et al.,* 2003), and the existence of *T. equiperdum* was even questioned.

Like all pathogenic trypanosomes, *T. evansi* is covered by a dense protein layer consisting of a single protein called the variable surface glycoprotein (VSG). This acts as a major immunogen and elicits the formation of specific antibodies. The parasites are able to evade the consequences of these immune reactions by switching the VSG, a phenomenon known as antigenic variation.

Clinical suspicion of surra can emerge from the field in case of fever and/or anaemia. Anaemia is a reliable indicator of trypanosome infection, but it is not in itself pathognomonic. On the other hand, animals with a mild subclinical infection can have parasitaemia without evidence of anaemia (Dargantes *et al.,* 2005a).

In enzootic areas, routine diagnoses can be made using parasitological techniques, while serological surveys can be carried out preferably by ELISA. CATT can be used to target individual animals for treatment with trypanocidal drugs.

Where a definitive confirmation of the infection in suspected animals is needed (e.g. for importation into a disease-free area), mouse inoculation is the best test to apply. However, animal testing should be limited and used only if fully justified.

For declaring disease-free status, at the individual level, serial testing by CATT and ELISA at 40-day intervals is recommended. However the conditions for importation of animals from infected to non-infected areas should be defined, including the status of the exporting farm, the status of exported animals, the application of a diagnostic protocol, and possibly the preventive administration of curative treatments.

In areas where *T. cruzi, T. equiperdum* or tsetse-transmitted trypanosomoses are present, cross-reactions may occur with any serological test employed. In such conditions, the exact status of an animal regarding trypanosomosis cannot be established.

The OIE has published international standard monographs for trypanocidal drugs.

1. Zoonotic risk and biosafety requirements

Trypanosoma evansi is not known to have a zoonotic potential. It should be handled in the laboratory in accordance with the principles outlined in Chapter 1.1.4 *Biosafety and biosecurity: Standard for managing biological risk in the veterinary laboratory and animal facilities*.

B. DIAGNOSTIC TECHNIQUES

1. Identification of the agent

The classical direct parasitological methods for the diagnosis of trypanosomosis, namely microscopic examination of blood or lymph node material, are not highly sensitive, but a number of techniques, including enrichment of the sample, rodent inoculation and DNA methods may increase the sensitivity. In regions where other *Trypanozoon* spp. occur in addition to *T. evansi*, specific identification by microscopy is not possible; molecular tools are then very useful for species specific diagnosis.

1.1. Direct microscopic examination

1.1.1. Blood sampling

Trypanosoma evansi is a parasite of the blood and tissues. As for other trypanosomes, it is recommended that blood for diagnosis be obtained from peripheral ear or tail vein, even if the jugular vein is most often preferred for practical reasons. However it should be realised that less than 50% of infected animals may be identified by examination of blood.

Peripheral blood is obtained by puncturing a small vein in the ear or tail. Deeper samples are taken from a larger vein by syringe. Cleanse an area of the ear margin or tip of the tail with alcohol and, when dry, puncture a vein with a suitable instrument (lancet, needle). Ensure that instruments are sterilised or use disposable instruments to avoid iatrogenic transmission of the infection by residual blood.

1.1.2. Wet blood films

Place a small drop of blood (2–3 µl) on to a clean glass slide and place over it a cover-slip to spread the blood as a monolayer of cells. Examine by light microscopy (200×) to detect any motile trypanosomes. Improved visualisation can be obtained with dark-ground or phase-contrast microscopy (200–400×). The sensitivity of this method is low, approximately 10 trypanosomes per µl, which is frequent in early or acute infections only.

1.1.3. Stained thick smears

Place a large drop of blood (10 µl) on the centre of a microscope slide and spread with a toothpick or the corner of another slide so that an area of approximately 1.0–1.25 cm in diameter is covered. Air-dry for 1 hour or longer, while protecting the slide from insects. Placing the slide in a horizontal position, stain the unfixed smear with Giemsa's Stain (one drop of commercial Giemsa + 1 ml of phosphate-buffered saline, pH 7.2), for 25 minutes. After washing and drying, examine the smears by light microscopy at a magnification of 500× with oil immersion. The advantage of the thick smear technique is that it concentrates the drop of blood into a small area, and thus less time is required to detect the parasites, which are more visible owing to the haemolysis of the unfixed red cells. The disadvantage is that the trypanosomes may be damaged in the process, and the method is therefore not suited for species identification in case of mixed infections.

1.1.4. Stained thin smears

Place a small drop of blood (3–5 µl) at one end of a clean microscope slide and draw out a thin film in the usual way. Air-dry briefly and fix in methyl alcohol for 1 minute and allow to dry. Stain the smears in Giemsa (one drop Giemsa + 1 ml PBS, pH 7.2) for 25 minutes. Pour off stain and wash the slide in tap water and dry. Nowadays, fast stains are most often used[1], which allow fixation and staining within a few seconds. Slides are then washed in tap water and dried. Examine at a magnification of 400–1000× with oil immersion. This technique permits detailed morphological studies and identification of the *Trypanosoma* species, but it is of a very low sensitivity (it can detect parasitaemia >500,000 trypanosomes/ml of blood).

1.1.5. Lymph node biopsies or oedema fluid

Samples are usually obtained from the prescapular or precrural (subiliac) lymph nodes. Select a suitable node by palpation and cleanse the site with alcohol. Puncture the node with a suitable gauge needle, and draw lymph node material into a syringe attached to the needle. Expel lymph on to a slide, cover with a cover-slip and examine as for the fresh blood preparations. Fixed thin

---

1   For example Diff-Quick®, RAL555®

or thick smears can also be stored for later examination. Similar examination can be done by collection of oedema fluid.

1.2. Concentration methods

In most hosts *T. evansi* can induce mild clinical or subclinical carrier state infections with low parasitaemia in which it is difficult to demonstrate the parasites. In these circumstances, concentration methods are necessary, as they increase the sensitivity of microscopic examination.

1.2.1. Haematocrit centrifugation technique (also known as Woo's technique, or HCT)

Collect blood (70 µl) into two heparinised capillary tubes (75 × 1.5 mm). Close the wet end with plasticine and centrifuge at 3000 ***g*** for 5 minutes (generally 12,000 rpm in a haematocrit centrifuge machine). The capillary tube is examined and the value of the haematocrit is expressed as a percentage of packed red blood cells (RBCs) to total blood volume; this gives an indication on the anaemia of the animal. The capillary tube is then placed in a groove made with pieces of slide glued to a slide. Trypanosomes are large cells that concentrate at the junction between the buffy coat and the plasma, which is observed under the microscope (100–200×). Light conditions must be set to induce refringence of the cells to increase the visibility of the moving trypanosomes; this can be obtained by lowering the position of the light condenser or with intermediary positions of the turret light condenser. Specially designed reading chambers for HCT can be obtained at the OIE Reference Laboratory for Surra, at the Institute of Tropical Medicine (ITM)[2]. The fresher the sample, the better is the sensitivity as strong parasitic movements make trypanosomes more visible. This technique can detect around 50–200 trypanosomes/ml of blood (Desquesnes & Tresse, 1996). The buffy coat can also be collected in a microtube and frozen; also the sample can be prepared for polymerase chain reaction (PCR).

1.2.2. Dark-ground/phase-contrast buffy coat method (also known as Murray's technique, or BCM)

This technique is very similar to the previous one. Collect blood into heparinised capillary tubes and centrifuge as above. Scratch the tube with a glass-cutting diamond and break it 0.5 mm below the buffy coat layer – the upper part thus contains a small top layer of RBCs, the buffy coat (white blood cells and platelets) and some plasma.

Partially expel the contents of this piece on to a slide; avoid expelling more than 5–8 µl of plasma, but make sure the buffy coat has been expelled (the small disk of the buffy coat should be visible to the naked eye), press on a cover-slip to spread the buffy coat and examine by dark-ground, phase-contrast or similar microscopy under the previously described refringent conditions at a magnification of 200–500×. Trypanosomes are mostly present at the periphery of the thick buffy coat material.

Both the Woo and the Murray techniques allow anaemia to be estimated by measuring the packed cell volume and may be used in surveys of herds at risk. The value of the haematocrit can be used as an indicator (when <24% for example in cattle) to select a subset of samples to be submitted to the more expensive PCR analysis (Desquesnes *et al.*, 1999).

1.2.3. Mini-anion exchange centrifugation technique

When a blood sample from animals infected with salivarian trypanosomes is passed through an appropriate DEAE-cellulose (diethylamino-ethylcellulose, such as Whatman DE 52) anion-exchange column, the host blood cells, being more negatively charged than trypanosomes, can be adsorbed onto the anion-exchanger (in pH and ionic strength conditions adapted to the host species), while the trypanosomes are eluted, retaining viability and infectivity (Lanham & Godfrey, 1970). This technique is mostly used for the purification of parasites from the blood (for example, for parasite antigen preparation), but miniature systems have been developed, especially for diagnosis in humans (Lumdsen *et al.,* 1981). A simplified field method for detection of low parasitaemia has been developed (Sachs, 1984). The sensitivity of this technique can be increased by approximately tenfold by the use of buffy coat preparations rather than whole blood (Reid *et al.,* 2001).

---

2   Laboratory of Parasite Diagnostic, Institute of Tropical Medicine, Nationalestraat 155, B-2000 Antwerp, Belgium. pbuscher@itg.be

i) *Preparation of phosphate buffered saline glucose (PSG), pH 8*

Na_2HPO_4 anhydrous (13.48 g); $NaH_2PO_4.2H_2O$ (0.78 g); NaCl (4.25 g); distilled water (1 litre). Solutions of different ionic strength are made by diluting the stock PBS, pH 8, and adding glucose to maintain a suitable concentration. For blood of mice, domestic and wild ruminants and dog, add four parts PBS to six parts distilled water and adjust the final glucose concentration to 1%. For blood of pigs and rabbits, add three parts PBS to seven parts distilled water and adjust the final glucose concentration to 1.5%. The PBS/glucose solution (PSG) must be sterile (however, PBS must be autoclaved before adding glucose).

ii) *Equilibration of DEAE-cellulose*

Suspend 500 g of DEAE-cellulose in 2 litres of distilled water. Mix for 20 minutes with a magnetic stirrer at low speed. Adjust the pH to 8 with phosphoric acid. Allow to settle for 30 minutes. Discard the supernatant fluid containing the finest granules. Repeat the procedure three times. Store the equilibrated concentrated suspension of DEAE-cellulose (slurry) at 4°C for a short period, or in small aliquots at –20°C for longer conservation.

iii) *Packing of equilibrated DEAE-cellulose*

Place a 2 ml syringe without the plunger on a test-tube rack complete with a flexible tube that can be closed with a clamp to act as a tap. Put a disc of Whatman No. 41 filter paper at the bottom of the syringe and moisten by adding a few drops of PSG. Pour 2–2.5 ml of the slurry of equilibrated cellulose into the syringe and allow packing for 5 minutes before elution of the buffer. The height of the sediment should be approximately 3 cm. Wash and equilibrate the column with 2 ml of PSG without disturbing the surface.

iv) *Adsorption of blood eluate of the trypanosomes*

Gently place 100–300 µl of heparinised blood (or preferably buffy coat) on the surface of the cellulose column; allow it penetrate the cellulose, but do not let the cellulose dry before pouring on the eluting buffer. Progressively add 1.5 ml of PSG and start collecting the eluate into a finely tapered Pasteur pipette with a sealed end. The cellulose column should remain wet throughout the procedure. Put the filled pipette, protected by a conical plastic pipette tip, in a tube and centrifuge at 525 *g* (or up to 1000 *g*) for 10 minutes. Examine the bottom of the pipette under the microscope (100× or 200×) using a special mounting device. Alternatively, the eluate could be collected into 50 ml plastic tubes, with conical bottoms, centrifuged at 1000 *g* and the sediment examined by dark-ground microscopy.

A similar method used in cattle, pig and goat is also referred to as the miniature anion exchange chromatography method (Gutierrez *et al.*, 2004a; Reid *et al.,* 2001; Sachs, 1984). In addition, large amounts of blood or buffy coat can be applied to large columns for preparation of antigen for indirect fluorescence antibody test (IFAT), card agglutination test (CATT) or enzyme linked immunosorbent assay (ELISA).

1.3. Animal inoculation

Due to the increasing concern to eliminate the use of animals for biological testing, animal inoculation should be limited as far as possible and only used if fully justified. Laboratory animals may be used to reveal subclinical (non-patent) infections in domesticated animals. *Trypanosoma evansi* has a broad spectrum of infectivity for small rodents, and so rats and mice are often used. Rodent inoculation is not 100% sensitive (Monzon *et al.,* 1990) but further improvement in its efficacy can be obtained by the use of buffy coat material. Such a procedure was able to detect as few as 1.25 *T. evansi*/ml blood (Reid *et al.,* 2001). This technique is suitable when highly sensitive detection is required.

Inoculate heparinised blood intraperitoneally into rats (1–2 ml) or mice (0.25–0.5 ml). Inoculate a minimum of two animals. Bleed animals from the tail after every 48 hours to detect parasitaemia. The incubation period before appearance of the parasites and their virulence depends on the strain of trypanosomes, their concentration in the inoculum, and the strain of laboratory animal used; however in most cases it is very short (5 ± 2 days), but can extend to 2 weeks in rare cases (Monzon *et al.,* 1990). Sensitivity of this *in vivo* culture system may be increased by use of immunosuppressed laboratory animals. Drugs such as cyclophosphamide or hydrocortisone acetate, X-ray irradiation, or splenectomy have been used for this purpose. Such a procedure is only justified when the detection of a potentially infected host is of high importance (for example, importation into a disease-free area).

1.4. Detection of trypanosomal DNA

Detection of minute amounts of trypanosomal DNA is a possible mean of identifying animals with active infections as the parasitic DNA does not remain for more than 24–48 hours in the blood of the host after the trypanosomes are killed (Desquesnes, 1997b).

1.4.1. DNA probes

Specific DNA probes have been used to detect trypanosome DNA in infected blood or tissue but are not routinely applied as further evaluation needs to be made (Basagoudanavar *et al.,* 2001; Reid *et al.,* 2001; Viseshakul & Panyim, 1990). PCR techniques are generally preferred and are routinely used in some laboratories.

1.4.2. Polymerase chain reaction (PCR)

Polymerase chain reaction (PCR) based on DNA sequences of various taxonomic levels is used. The gold standard, to date, for detection of the *Trypanozoon* subgenus are the NRP or TBR primers (Masiga *et al.,* 1992; Moser *et al.,* 1989). Other primers have been published and are being evaluated; some of them are specific for *Trypanozoon* (Desquesnes *et al.*, 2001; Holland *et al.*, 2001; Wuyts *et al.,* 1994) and others for *T. evansi* ± *T. equiperdum* (Artama *et al.,* 1992; Claes *et al.*, 2004; Panyim *et al.,* 1993) (evaluation of the latter is very difficult because of the absence of collections of reference strains). To date, the most sensitive test is that of satellite DNA using TBR primers (Masiga *et al.,* 1992); the sensitivity of the other primers is being compared under various conditions, including in laboratory rodents, but can only be validated with a sufficient batch of field samples from natural hosts. The use of TBR primers is recommended, at least in the first instance, and, if necessary, for example in areas and host species potentially infected with other *Trypanozoon* such as *T. brucei brucei*, species confirmation can be obtained with more specific primers such as TEPAN (Panyim *et al.,* 1993) or TE2249/2250 (Artama *et al.,* 1992). Other primers specific for RoTat (Claes *et al.,* 2004; Verloo *et al.,* 2001) or non-RoTat strains (Ngaira *et al.,* 2005), and other techniques such as the loop-mediated isothermal amplification (LAMP) (Thekisoe *et al.,* 2005) and Taqman (Taylor *et al.,* 2008), are under development but need to be further evaluated and validated.

DNA preparation is an important step that determines the success and the sensitivity of the PCR. It can be done on plain blood (generally collected with anticoagulant), or, preferably, on the buffy coat to increase the sensitivity of the test (Desquesnes & Davila, 2002; Majiwa *et al.,* 1994). Several classical techniques are available, such as Chelex preparation (Solano *et al.,* 1999), commercial kits and the phenol–chloroform preparation (Maciel *et al.,* 2009). Blood conserved 1/1 in 70% alcohol, or on dry filter paper can also be used (Desquesnes, 2004; Holland *et al.*, 2002; Omanwar *et al.,* 1999).

The sensitivity of the PCR being dependent on the amount of DNA available, it is proportional to the parasitaemia. PCR is thus more sensitive in highly susceptible hosts (camels, horses, dogs, etc.) than in hosts of mild or low susceptibility (cattle, buffalo, pigs, etc.). Using a suitable DNA preparation and the most sensitive primers available (TBR), PCR allows as little as 1–5 trypanosomes/ml of blood to be detected (Panyim *et al.,* 1993; Penchenier *et al.,* 1996), or only 10 per ml in buffaloes with a quantitative real-time PCR (Konnai *et al.,* 2009).

PCR offers the sensitivity and specificity required for detection of trypanosome infection (Masiga *et al.,* 1992; Wuyts *et al.,* 1994; 1995), but it may give false-negative results. Experimental studies in sheep have shown that PCR can remain negative for long intervals during aparasitaemic periods (Bengaly *et al.*, 2001), while in buffalo the diagnostic sensitivity of a PCR was only 78%, which is similar to mouse inoculation (Holland *et al.*, 2001). Nevertheless, PCR is the most sensitive technique for detection of the infection.

1.5. Antigen detection

Circulating antigen detection in blood or serum is also a way to detect active infection. Several attempts to develop such tests have not yet reached a satisfactory level to be recommended for routine diagnosis (Desquesnes, 1996; Monzon, 2006; Morzaria *et al.,* 1996).

2. Serological tests

Historically, different methods have been used to detect non-specific humoral antibodies present in cases of surra infection. These methods are biochemical tests including flocculation, formol-gel, mercuric chloride precipitation

and thymol turbidity tests, and are considered to be outdated although the formol-test may still have some use in the field because it is simple to perform. These tests all depend on an increase in serum globulins as a result of infection, but this increase is not specific for *T. evansi* infection. Mercuric chloride must not be used because of its toxicity. The formol-gel test is the test of choice in camels but has not been validated in other species. It is carried out by adding two drops of concentrated formalin solution (40% formaldehyde [w/v]) to 1 ml of serum. The test is positive if the serum coagulates immediately and turns white. In negative reactions, the serum remains unchanged or coagulation may take up to 30 minutes to appear.

Similarly, many different methods have been used to detect specific humoral antibodies to trypanosomal antigens, such as direct or indirect agglutination tests, complement fixation test (CFT), IFAT (Desquesnes, 1997a; Uilenberg, 1998) and the trypanolysis test. The IFAT is still useful for small-scale surveys. The trypanolysis test is used for individual confirmation of positivity because of its high specificity. The other tests are no longer used because they have been replaced by the more easily standardised techniques of ELISA (Davison *et al.,* 1999; Franke *et al.,* 1994; Rae *et al.*, 1989; Reid & Copeman, 2002; 2003; Tuntasuvan *et al.,* 1996) and CATT (Bajyana Songa & Hamers, 1988; Njiru *et al.*, 2004). Attempts to develop new techniques such as latex agglutination tests have not been successful so far (Gutierrez *et al.*, 2004b; Holland *et al.*, 2005; Morzaria *et al.,* 1996).

Evaluations of ELISA and CATT have been carried out in camels, horses, cattle, buffaloes and pigs (Desquesnes *et al.,* 2009; Diall *et al.,* 1994; Holland *et al.*, 2005; Payne *et al.* 1991; Reid & Copeman, 2003; Verloo *et al.,* 2000). Tests should preferably be carried out on plasma or serum, but the collection of samples can be simplified by using filter paper blood spots for later use in the ELISA, while for the CATT whole blood can be substituted for serum (Holland *et al.*, 2002; Hopkins *et al.,* 1998). It is vitally important that serological tests be validated and standardised if they are to be suitable for correctly identifying infected animals; cross evaluation in different laboratories is thus required. Standard criteria for interpreting the tests might have to be developed for each animal species and standardised at least at a regional level (Desquesnes, 1997c). It is also necessary to take into consideration the various *Trypanosoma* species and strains (RoTat *versus* non-RoTat for example) present in a given area.

2.1. Indirect immunofluorescent antibody test (IFAT)

Although the technique is not adapted to large-scale surveys, it is still useful to screen a small number of samples in laboratories that are carrying out the test for other purposes and/or that are not carrying out the ELISA. Cost of reagents is medium, around 0.5€/test, but the technique is time consuming.

2.1.1. Test procedure

The antigen consists of dried blood smears containing from five to ten *T. evansi* per field at magnification 500×, collected from a highly parasitaemic mouse or rat (3–4 days post-infection). Smears are dried at room temperature for 1 hour and fixed with acetone (± ethanol) for 5 minutes. When kept dry, the fixed smears may be stored at –20°C for several months. Better results are obtained using purified trypanosomes separated from the rat's buffy coat on a DEAE-cellulose column (Lanham & Godfrey, 1970) using a mixture of 80% cold acetone and 0.25% formalin in a normal saline solution.

On testing, the slides are first subdivided into several circles of 5 mm diameter with nail varnish using mounting media (Teflon-coated multispot slides may also be used), then washed in PBS, pH 7.2, at room temperature for 10 minutes.

After washing, a positive and a negative control serum and field sera to be tested (diluted 1/50 in PBS), are added and allowed to react at 37°C for 30 minutes in a humid chamber. The slides are washed three successive times in PBS for 5 minutes each. A rabbit or goat anti-bovine IgG (for tests on bovine sera) conjugated to fluorescein isothiocyanate or other fluorescein-conjugated antiserum specific to the animal species tested is then added at a suitable dilution and left at 37°C for 30 minutes in a humid chamber. The slides are rewashed in PBS, mounted with 50% glycerol in PBS with immunofluroescence mounting media, and examined by fluorescence microscopy. The glycerol solution should be stored at 4°C and renewed every 2 weeks.

The fluorescein conjugate should be stored at –20°C in small aliquots to avoid repeated freezing and thawing. The tube should be shielded from light in some way, for example by wrapping in aluminium foil. The conjugate is diluted in PBS, pH 7.2, or in PBS containing Evans blue 1/1000 (w/v) as a counterstain to facilitate discrimination between positive (green) and negative (red) fluorescence. In general, monospecific anti-IgG (gamma-chain) conjugates give the most specific results.

The IFAT-*T. evansi* seroconversion can take 60–90 days (Jacquiet *et al.*, 1993). Compared with the CATT, IFAT is more sensitive, probably because it can detect aparasitaemic animals, but specificity is lower (Dia *et al.,* 1997b). In borderline cases, the interpretation is subjective and reproducibility has sometimes been questioned (Ferenc *et al.,* 1990). For these reasons, ELISA is a more advisable technique.

2.2. Enzyme-linked immunosorbent assay (ELISA)

The principle of this technique is that specific antibodies to trypanosomes can be detected by enzyme-linked anti-immunoglobulins using solid-phase polystyrene plates coated with soluble antigen. The enzyme may be peroxidase, alkaline phosphatase or any other suitable enzyme. The enzyme conjugate binds to the antigen/antibody complex and then reacts with a suitable substrate to yield a characteristic colour change either of the substrate itself or of an added indicator (the chromogen).

The antigen for coating the plates is derived from the blood of a heavily parasitaemic rat. The trypanosomes are concentrated in the buffy coat by centrifugation and separated on a DEAE-cellulose column and washed three times by centrifugation in cold PSG, pH 8 (PBS with 1% glucose). The final pellet is suspended in cold PSG to a concentration of 5%, together with a protease inhibitor cocktail[3] subjected to five freeze–thawing cycles, and ultrasonicated three times for 2 minutes on ice to ensure complete disintegration of the organisms. This preparation is centrifuged at 4°C and 14,000 *g* for 10 minutes. The supernatant is collected and the protein concentration estimated by UV readings at 260 and 280 nm (Warburg & Christian, 1942). The soluble antigen thus obtained can be stored in small aliquots at –80°C for several months. It can also be freeze-dried and stored at –20°C. Coating of the ELISA plate is generally made with 5 µg/ml protein concentration in coating buffer.

2.2.1. Test procedure

i) Dilute the soluble antigen at 5 µg/ml in freshly prepared 0.01 M carbonate/bicarbonate buffer, pH 9.6. Add 100 µl to each well of a 96-well microtitre plate and incubate overnight at 4°C or for 1 hour at 37°C. For this step immunoplates that ensure that the specific activities of the epitopes are preserved during binding to the plate surface[4], are preferred to other plates that may allow epitopes to be obscured or impaired due to the binding characteristics.

ii) Remove antigen and add 150 µl of blocking buffer (BB: 0.01 M PBS containing 0.1% Tween 20 and 5% skim milk powder for 1 hour at 37°C. The quality of the skim milk is very critical[5]; optimal skim milk concentration may vary from 0.5 to 7% depending on the skim milk origin. Bovine serum albumin may also be used as blocking agent.

iii) Add test serum dilutions in BB (100 µl), in duplicate or triplicate. Include control negative and positive sera. Dilutions must be determined empirically, but are usually around 1/100–1/200. Incubate plates at 37°C for 30 minutes. Eject contents and wash five times with washing buffer (PBS-0.1% Tween 20).

iv) Add a specific peroxidase conjugated species-specific anti-globulin (100 µl) appropriately diluted in BB (usually between 1/5000 and 1/20,000). If species-specific conjugates are not available, protein A or protein G conjugates can be used. Incubate the plates at 37°C for 30 minutes, eject contents and wash three times with washing buffer.

v) For peroxidase conjugates a number of substrate/chromogen solutions can be used, consisting of hydrogen peroxide with a chromogen, such as tetramethylbenzidene (TMB), 2,2'-azino-bis-(3-ethylbenzothiazoline-6-sulphonic acid) (ABTS) or ortho-diphenylenediamine (OPD). A suitable substrate/chromogen solution for peroxidase conjugates is 30% hydrogen peroxide (0.167 ml and 35 mg) in citrate buffer (100 ml), pH 6.0. The citrate buffer is made up as follows: Solution A (36.85 ml): (0.1 M citric acid [21.01 g/litre]); Solution B (65.15 ml): (0.2 M, Na_2HPO_4 [35.59 g/litre]); and distilled water (100 ml). Dissolve 10 mg TMB in 1 ml dimethyl sulphoxide and add to 99 ml of the citrate buffer. A number of these combinations are available commercially in ready-to-use formulations that remain stable at 4°C for up to 1 year. Add the substrate chromogen (100 µl) to the plates and incubate at room temperature for 20–30 minutes.

vi) Read the plates or stop the reaction by adding 50 µl 1 M sulphuric acid. Read the absorbance of each well at 450 nm for TMB chromogen. Other chromogens may require the use of a different wavelength. All tests should include three known high and medium

---

3 Complete solution for protease inhibitor; Roche Molecular Biochemicals
4 For example Polysorp Nunc® immunoplates
5 For example: ref: 190-12865, Wako Pure Chemical Industries Ltd, Osaka, Japan.

positive control sera, three low and medium negative control sera, and a buffer control. Results are expressed in relative percentage of positivity (RPP) based on the optical densities of the control samples (Desquesnes, 1997c; Desquesnes *et al.,* 2009).

A large variety of other test procedures exists, for example, using purified native antigen (Verloo *et al.,* 1998) or, more recently, using recombinant antigens (Tran *et al.,* 2009). For closely related animal species, cross-reacting reagents may often be used (e.g. anti-bovine immunoglobulin for buffalos) and the use of monospecific anti-IgG conjugates is generally recommended. However, when specific conjugates are not available, nonspecific proteins able to fix on the Fc fragment of the immunoglobulins can be used, such as protein A (for detection of IgG) or protein G (for detection of IgM). Protein A conjugate has been validated for use in camels (Desquesnes *et al.*, 2009).

There is a number of methods that can be used to determine a cut-off point to discriminate between positive and negative results. The simplest method is to base the cut-off on visual inspection of the test results from known positive and negative populations (Desquesnes, 1997c). These results are likely to show some overlap. The operator can choose the most appropriate point to modify the false-positive or false-negative results depending on the required application of the assay. An alternative is to base the cut-off on the mean + 2 standard deviations (SD) or + 3 SD values from a large sample of negative animals. Finally, if no suitable negative/positive samples are available, a cut-off can be based on the analysis of the data from animals in an endemic situation (Greiner *et al.*, 1994). If a bimodal distribution separates infected from uninfected animals, then an appropriate value can be selected. The ELISA is likely to correctly identify uninfected animals (while the CATT would correctly qualify infected ones). A new ELISA/RoTat 1.2 based on the VSG from a *T. evansi* RoTat 1.2 clone – a predominant antigen in *T. evansi* (Verloo *et al.,* 2001) – was successfully used in the field in Vietnam (Holland *et al.*, 2002; Verloo *et al.,* 2000); protocols are available from the OIE Reference Laboratory at ITM (Antwerp) for use in equines, camelidae and water buffaloes. Another test based on invariant surface glycoprotein has recently been developed at the ITM (Tran *et al.,* 2009) and should proceed to inter-laboratory evaluation.

The VSGs may be too specific to be used as antigen in a universal test (see below RoTat *versus* non-RoTat parasites), while the ELISA using soluble antigens is not strain specific and this qualifies it as a universal test. Soluble antigens from whole lysate of *T. evansi* are able to detect immunoglobulins directed against *T. evansi* strains present in various host species and geographical areas (Laha & Sasmal, 2008); they can also detect infections in heterologous systems owing to strong cross reactions with *T. vivax*, *T. congolense* and even *T. cruzi. Trypanosoma evansi* soluble antigen must then be considered as a universal reagent for detection of *T. evansi*, but consideration must be given to species specificity in multispecies areas. The cost of reagents is low, around 0.1€/test, and the technique is fast, allowing 500–1000 samples to be tested a day by experienced technicians.

2.3. Card agglutination tests

It is well known that certain predominant variable antigen types (VATs) are expressed in common in different strains of salivarian trypanosomes from different areas. This finding was used as a basis for a test for the diagnosis of *T. evansi*, the card agglutination test – CATT/*T.evansi.* The test makes use of fixed and stained trypanosomes of a defined VAT known as RoTat 1.2. Both variable and invariable surface antigens take part in the agglutination reaction. The CATT is available in kit form from the OIE Reference Laboratory ITM. It consists of lyophilised stained parasites ('antigen'), PBS, pH 7.4, plastic-coated cards, spatulas, positive and negative control sera and a rotator. The lyophilised antigen can be stored at 2–8°C for up to 1 year. Reconstituted antigen can be stored at 2–8°C for 1 week, but preferably should be used within 8 hours when kept at 37°C.

For screening, dilute test sera 1/4 or 1/8 in PBS on to circles inscribed on the plastic cards. Add 45 μl of the prepared antigen suspension (previously well shaken to homogenise the parasite suspension) onto circles inscribed on the plastic cards. Add 25 μl of each test serum. Mix and spread the reagents with a spatula and rotate the card for 5 minutes using the rotator provided in the kit (or at 70 rpm on a classical rotor agitator). Compare the pattern of agglutination with the illustrations of different reactions provided in the kit. Blue granular deposits reveal a positive reaction visible to the naked eye. The cost of reagents is medium, around 0.5€/test, around 200 tests can be carried out a day by one technician.

As the CATT principally detects IgM (agglutinating pentavalent immunoglobulins the half-life of which is short), it is suitable for detection of early infections or late infections with recent circulation of parasites in the blood, and can detect active infections with a high positive predictive value. The CATT is more likely to classify correctly truly infected animals, it can be used to target individual animals for treatment with trypanocidal drugs.

An alternative test format (LATEX/*T.evansi*) using latex beads coated with native RoTat 1.2 VSG is currently under evaluation.

2.4. Immune trypanolysis test

Immune trypanolysis test detects specific 'trypanolytic' antibodies directed against a given parasitic strain able to induce trypanolysis in the presence of complement. It is performed with *T. evansi* variable antigen type RoTat 1.2 and may therefore be positive only with hosts that produce trypanolytic immunoglobulins directed against RoTat 1.2 VAT (Van Meirvenne *et al.,* 1995). Sera are tested at a 1/4 dilution. Live trypanosomes are incubated for 60 minutes with test serum in the presence of guinea-pig serum as the source of complement. When variant specific antibodies are present in the serum, lysis of the RoTat 1.2 trypanosomes occurs. The sample is considered positive for the presence of anti-RoTat 1.2 antibodies when 50% or more of the trypanosomes are lysed. This test requires the growth of trypanosomes in rodents and is thus costly. At present, it is mostly used to confirm samples suspected to be positive using other tests. It can be carried out at the ITM, Antwerp, on request. The cost of the test is very high (250€/test).

3. Test applications

Like the majority of biological tests, the methods described above are limited both in terms of sensitivity and specificity. Moreover, test performances and parameters are highly variable, depending on the host species or the geographical area in which the host occurs. To date, there is no common test (parasitological, serological or even molecular) that is capable of distinguishing *T. evansi* from the other *Trypanozoon* species or sub-species. The final diagnosis of surra will depend on epizootiological information and laboratory results and observations. For these reasons, a number of test combinations adapted to the different circumstances relevant to a particular host species are currently recommended. These are guidelines that should be helpful in achieving the correct diagnoses.

3.1. Recommended methods

i) *Microscopic examination:* Microscopic observation ($\times$400–1000 in oil immersion) of a Giemsa-stained thin blood smear from the host, or from a mouse inoculation test, allows identification of the subgenus *Trypanozoon* based on morphology and morphometry of parasites. When fresh samples are available, HCT or BCM must be used to increase the sensitivity.

ii) PCR-TBR: DNA must be prepared from blood with a commercial kit or phenol chloroform method, using a buffy coat obtained by 8000 **g** centrifugation of 0.5 ml of blood. PCR is carried out as described above, with TBR primers (Masiga *et al.,* 1992). Result is positive for *Trypanozoon* when a 177 bp product is visible on the agarose gel.

iii) ELISA *T. evansi:* Serum or plasma samples are tested in ELISA-*T. evansi* (soluble antigens from whole *T. evansi* lysate) as described above. A sample is positive when its RPP is > than the cut off value established for the host species (appropriate conjugates are defined for each species; see (d) below).

iv) CATT/*T. evansi:* Serum or plasma are diluted 1:4 and tested as described by the manufacturer. Positive samples are samples presenting results = or > to one + (doubtful samples are considered as negative samples).

3.2. Equids

An equid is negative to surra if it is negative to ELISA-*T. evansi* (anti-horse IgG whole molecule), CATT/*T. evansi*, PCR-TBR and microscopic examination.

An animal is considered to be infected by *Trypanozoon* spp. if it is positive to PCR-TBR and/or if *Trypanozoon* parasites are observed by microscopic examination.

An animal is considered as seropositive to surra if it is positive to ELISA-*T. evansi* and/or CATT/*T. evansi*; in this case, the animal should be tested for CFT-dourine, and, if it is positive for CFT-dourine it is also considered as seropositive to dourine; if it is negative to CFT-dourine, it is considered as seropositive to surra only.

3.3. Camelids

An animal is negative to surra if it is negative to ELISA-*T. evansi* (protein A conjugate), CATT/*T. evansi*, PCR-TBR and microscopic examination.

An animal is considered as infected by *Trypanozoon* spp*.* if it is positive to PCR-TBR and/or microscopic examination.

An animal is considered as seropositive to surra if it is positive to ELISA-*T. evansi* and/or CATT/*T. evansi.*

3.4. Other host species

An animal is negative to surra if it is negative to ELISA-*T. evansi* (conjugate see below), CATT/*T. evansi*, PCR-TBR and microscopic examination.

An animal is considered as infected by *Trypanozoon* spp*.* if it is positive to PCR-TBR and/or microscopic examination.

An animal is considered as seropositive to surra if it is positive to ELISA-*T. evansi* and/or CATT/*T. evansi.*

Conjugates to be used for each host species: Cattle and buffalo: anti-bovine IgG whole molecule; Pig and elephant: Protein G conjugate; Camels: Protein A conjugate; Rat: anti-rat IgG whole molecule. Conjugates remain to be defined for other host species.

C. REQUIREMENTS FOR VACCINES

No vaccines are available for this disease.

REFERENCES

ARTAMA W.T., AGEY M.W. & DONELSON J.E. (1992). DNA comparisons of *Trypanosoma evansi* (Indonesia) and *Trypanosoma brucei* spp. *Parasitology*, **104**, 67–74.

BASAGOUDANAVAR S.H., RAO J.R., OMANAWAR S., TIWARI A.K., SINGH R.K., KARTARIA R.S. & BUTCHAIAH G. (2001). Identification of *Trypanosoma evansi* by DNA hybridisation using a non-radioactive probe generated by arbitrary primer PCR. *Acta Vet. Hung,* **49**, 191–195.

BAJYANA SONGA E. & HAMERS R. (1988). A card agglutination test (CATT) for veterinary use based on an early VAT RoTat 1–2 of *Trypanosoma evansi. Ann. Soc. Belg. Med. Trop.*, **68**, 233–240.

BENGALY Z., KASBARI M., DESQUESNES M. & SIDIBE I (2001). Validation of a polymerase chain reaction assay for monitoring the therapeuthic efficacy of diminazene aceturate in trypanosome-infected sheep. *Vet. Parasitol.,* **96**, 101–113.

BRUN R., HECKER H. & LUN Z.R. (1998). *Trypanosoma evansi* and *T. equiperdum:* distribution, biology, treatment and phylogenetic relationship (a review). *Vet. Parasitol.,* **79**, 95–107.

CLAES F., AGBO E.C., RADWANSKA M., TE PAS M.F.W., BALTZ T., DE WAAL D.T., GODDEERIS B.M., CLASSEN E. & BUSCHER P. (2003). How does *Trypanosoma equiperdum* fit into the *Trypanozoon* group? A cluster analysis by RAPD and multiplex-endonuclease genotyping approach. *Parasitology*, **26**, 425–431

CLAES F., BUSCHER P., TOURATIER L. & GODDEERIS B.M. (2005). *Trypanosoma equiperdum:* master of disguise or historical mistake? *Trends Parasitol.*, **21**, 316–321.

CLAES F., RADWANSKA M., URAKAWA T., MAJIWA P.A., GODDEERIS B. & BUSCHER P. (2004) Variable surface glycoprotein RoTat 1.2 PCR as a specific diagnostic tool for the detection of *Trypanosoma evansi* infections. *Kinetoplastid Biol. Dis.*, **3**, 3.

DARGANTES A.P., REID S.A. & COPEMAN D.B. (2005a). Experimental *Trypanosoma evansi* infection in the goat. I Clinical signs and pathology. *J. Comp. Pathol.*, **133**, 261–266.

DARGANTES A.P., REID S.A. & COPEMAN D.B. (2005b). Experimental *Trypanosoma evansi* infection in the goat. II Pathology. *J. Comp. Pathol.*, **133**, 267–276.

DAVISON H.C., THRUSFIELD M.V., MUHARSINI S., HUSEIN A., PARTOUTOMO S., MASAKE R. & LUCKINS A.G. (1999). Evaluation of antigen- and antibody-detection tests for *Trypanosoma evansi* infections of buffaloes in Indonesia. *Epidemiol. Infect.,* **123**, 149–155.

DESQUESNES M. (1996). Evaluation of three antigen detection tests (monoclonal trapping ELISA) for African trypanosomes, with an isolate of *T. vivax* from French Guyana. *Ann. NY Acad. Sci.*, **791**, 172–184.

DESQUESNES M. (1997a). Les trypanosomoses du bétail en Amérique Latine, étude spéciale dans le Plateau des Guyanes. PhD Thesis, Lille II University, 26 septembre 1997, Lille, France, 409 p.

DESQUESNES M. (1997b). Evaluation of a simple PCR technique for the diagnosis of *Trypanosoma vivax* in the serum of cattle in comparison to parasitological techniques and antigen-enzyme linked immunosorbent assay (Ag-ELISA). *Acta Trop.*, **65**, 139–148.

DESQUESNES M. (1997c). Standardisation internationale et régionale des épreuves immuno-enzymatiques: méthode, intérêts et limites. *Rev. sci. tech. Off. int. Epiz.,* **16**, 809–823.

DESQUESNES M. (2004). Livestock trypanosomoses and their vectors in Latin America. 2004, CIRAD-EMVT publication, OIE, Paris, France, ISBN 92-9044-634-X. 174 p.

DESQUESNES M., BOSSARD G., THEVENON S., PATREL D., RAVEL S., PAVLOVIC D., HERDER S., PATOUT O., LEPETITCOLIN E., HOLLZMULLER P., BERTHIER D., JACQUIET P. & CUNY G. (2009). Development and application of an antibody-ELISA to follow up a *Trypanosoma evansi* outbreak in a dromedary camel herd in France. *Vet. Parasitol.*, **162**, 214–220.

DESQUESNES M. & DAVILA A.M. (2002). Applications of PCR-based tools for detection and identification of animal trypanosomes: a review and perspectives. *Vet. Parasitol.*, **109**, 213–231.

DESQUESNES M., MCLAUGHLIN G., ZOUNGRANA A. & DÁVILA A.M.R. (2001). Detection and identification of *Trypanosoma* of African livestock through a single PCR based on internal transcribed spacer 1 of rDNA. *Int. J. Parasitol.*, **31**, 610–614.

DESQUESNES M., MICHEL J.F., DE LA ROCQUE S., SOLANO P., MILLOGO L., BENGALY Z. & SIDIBE I. (1999). Enquête parasitologique et sérologique (ELISA-indirectes) sur les trypanosomoses des bovins dans la zone de Sidéradougou, Burkina Faso. *Rev. Elev. Med. Vet. Pays Trop.*, **52**, 3–4.

DESQUESNES M. & TRESSE L. (1996). Evaluation de la sensibilité du test de WOO pour la détection de *Trypanosoma vivax*. *Rev. Elev. Med. Vet. Pays Trop.*, 1996. **49**, 315–321.

DIA M.L., DIOP, C., AMINETOU M., JACQUIET P. & THIAM A. (1997a). Some factors affecting the prevalence of *T. evansi* in camels in Mauritania. *Vet. Parasitol.*, **72**, 111–120.

DIA M.L., VAN MEIRVENNE N., MAGNUS E., LUCKINS A.G., DIOP C., THIAM A., JACQUIET P. & HAMERS R. (1997b). Evaluation de 4 tests de diagnostic: Frottis sanguins, CATT, IFI et ELISA-Ag dans l'étude de l'épidémiologie de la trypanosomose cameline à *Trypanosoma evansi* en Mauritanie. *Rev. Elev. Med. Vet. Pays Trop.*, **50**, 29–36.

DIALL O., BAJYANA SONGA E., MAGNUS E., KOUYATE B., DIALLO B., VAN MEIRVENNE N. & HAMERS R. (1994). Evaluation of a direct serologic card agglutination test for the diagnosis of camel trypanosomiasis caused by *Trypanosoma evansi*. *Rev. Sci. Tech.*, **13**, 793–800.

FERENC S.A., STOPINSKI V. & COURTENEY C.H. (1990). The development of an enzyme-linked immunosorbent assay for *Trypanosoma vivax* and its use in a seroepidemiological survey in the eastern Caribbean basin. *Int. J. Parasitol.*, **20**, 51–56.

FRANKE C.R., GREINER M. & MEHLITZ D. (1994). Investigations on naturally occurring *Trypanosoma evansi* infections in horses, cattle, dogs and capybaras *(Hydrochaeris hydrochaeris)* in Pantanal de Pocone (Mato Grosso, Brazil). *Acta Trop.,* **58***,* 159–169.

GILL B.S. (1977). Trypanosomes and trypanosomiases of Indian livestock. Indian Council of Agricultural Research, Edit. ICAR New Delhi, 1977, A booklet, 137 p.

GREINER M., FRANKE C.R., BOHNING D. & SCHLATTMANN P. (1994). Construction of an intrinsic cut off value for the sero-epidemiological study of *Trypanosoma evansi* infections in a canine population in Brazil: a new approach toward an unbiased estimaition of prevalence. *Acta Trop.*, **56**, 97–109.

GUTIERREZ C., CORBERA J.A., DORESTE F. & BUSCHER P. (2004a). Use of the miniature anion exchange centrifugation technique to isolate *Trypanosoma evansi* from goats. *Ann. NY Acad. Sci.*, **1026**, 149–151.

GUTIERREZ C., CORBERA J.A., JUSTE M.C., DORESTE F. & MORALES I. (2005). An outbreak of abortions and high neonatal mortality associated with *Trypanosoma evansi* infection in dromedary camels in the Canary Islands. *Vet. Parasit.*, **130**, 163–168.

GUTIERREZ C., CORBERA J.A., MORALES M. & BUSCHER P. (2004b). Performance of serological tests for *Trypanosoma evansi* in experimentally inoculated goats. *Ann. NY Acad. Sci.*, **1026**, 152–153.

HOLLAND W.G., CLAES F., MY L.N., THANH N.G., TAM P.T., VERLOO D., BUSCHER P., GODDEERIS B. & VERCRUYSSE J. (2001). A comparative evaluation of parasitological tests and a PCR for *Trypanosoma evansi* diagnosis in experimentally infected water buffaloes. *Vet. Parasit.*, **97**, 23–33.

HOLLAND W.G., THANH N.G., DO T.T., SANGMANEEDET S., GODDEERIS B. & VERCRUYSSE J. (2005). Evaluation of diagnostic tests for *Trypanosoma evansi* in experimentally infected pigs and subsequent use in field surveys in North Vietnam and Thailand. *Trop. Anim. Health Prod.*, **37**, 457–467.

HOLLAND W.G., THANH N.G., MY L.N., MAGNUS E., VERLOO D., BUSCHER P., GODDEERIS B. & VERCRUYSSE J. (2002). Evaluation of whole fresh blood and dried blood on filter paper discs in serological tests for *Trypanosoma evansi* in experimentally infected water buffaloes. *Acta Trop.*, **81**, 159–165.

HOPKINS J.S., CHITAMBO H., MACHILA N., LUCKINS A.G., RAE P.F., VAN DE BOSSCHE P. & EISLER M. (1998). Adaptation and validation of antibody-ELISA using dried blood spots on filter paper for emidemiological surveys of tsetse-transmitted trypanosomosis in cattle. *Prev. Vet. Med.*, **37**, 91–99.

JACQUIET P., CHEILH D., THIAM A. & DIA M.L. (1993). La trypanosomose à *Trypanosoma evansi* (Steel 1985), Balbiani 1988, chez les ruminants de Mauritanie. Résultats d'inoculations expérimentales et d'enquêtes sur le terrain. *Rev. Elev. Med. Vet. Pays Trop.*, **46**, 574–578.

JENSEN R.E., SIMPSON L. & ENGLUND P.T. (2008). What happens when *Trypanosoma brucei* leaves Africa. *Trends Parasitol.*, **24**, 428–431.

KONNAI S., MEKATA M., MINGALA C., ABES N., GUTIERREZ C., HERRERA J., DARGANTES A., WITOLA W., CRUZ L., INOUE N., ONUMA M. & OHASHI K. (2009). Development and application of a quantitative real-time PCR for the diagnosis of Surra in water buffaloes. *Infect. Genet. Evol.*, **4**, 449–452.

LAHA R. & SASMAL N.K. (2008). Characterization of immunogenic proteins of *Trypanosoma evansi* isolated from three different Indian hosts using hyperimmune sera and immune sera. *Res. Vet. Sci.*, **85**, 534–539.

LAI D.H., HASHIMI H., LUN Z.R., AYALA F.J. & LUKES J. (2008). Adaptations of *Trypanosoma brucei* to gradual loss of kinetoplast DNA: *Trypanosoma equiperdum* and *Trypanosoma evansi* are petite mutants of *T. brucei. Proc. Natl Acad. Sci. USA*, **105**, 1999–2004.

LANHAM S.M. & GODFREY D.G. (1970). Isolation of salivarian Trypanosomes from man and other mammals using DEAE – Cellulose. *Exp. Parasitol.,* **28**, 521–534.

LOHR K.F., PHOLPARK S., SIRIWAN P., LEESIRIKUL N., SRIKITJAKARN & STAAK C. (1986). *Trypanosoma evansi* infection in buffaloes in North-East Thailand. II. Abortions. *Trop. Anim. Health Prod.*, **18**, 103–108.

LUMDSEN W., KIMBER C., DUKES P., HALLER L., STANGHELLINI A. & DUVALLET G. (1981). Field dignosis of sleeping sickness in Ivory Coast 1. Comparison of the miniature anion-exchange centrifugation technique with other protozoological methodes. *Trans. R. Soc. Trop. Med. Hyg.*, **75**, 242–250.

MACIEL B.M., SANTOS A.C., DIAS J.C., VIDAL R.O., DIAS R.J., GROSS E., CASCARDO J.C. & REZENDE R.P. (2009). Simple DNA extraction protocol for a 16S rDNA study of bacterial diversity in tropical landfarm soil used for bioremediation of oil waste. *Genet. Mol. Res.*, **8**, 375–388.

MAJIWA P.A.O., THATTHI R., MOLOO S.K., NYEKO J.P.H., OTIENO L.H. & MALOO S. (1994). Detection of trypanosome infections in the saliva of tsetse flies and buffy coat samples from antigenaemic but aparasitaemic cattle. *Parasitology*, **108**, 1–10.

MASIGA D.K., SMYTH A.J., HAYES P., BROMIDGE T.J. & GIBSON W.C. (1992). Sensitive detection of trypanosomes in tsetse flies by DNA amplification. *Int. J. Parasitol.*, **22**, 909–918.

MONZON C.M. (2006). Characterisation of a monoclonal antibody against *Trypanosoma evansi* and its application for detecting circulating antibodies. *Rev. Sci. Tech.*, **25**, 1067–1074.

MONZON C.M., MANCEBO O.A. & ROUX J.P. (1990). Comparison between 6 parasitological methods for diagnosis of *Trypanosoma evansi* in the subtropical area of Argentina. *Vet. Parasitol.,* **36***,* 141–146.

MORZARIA S., MASAKE R., ROWLAND J. & MUSOKE T. (1996). Antigen ELISAs for trypanosomes; evaluation of the performance. Proceedings of a Workshop held at ILRI, Nairobi, Kenya, 9–11 December 1996, 129 p.

MOSER D.R., COOK G.A., OCHS D.E., BAILEY C.P., MCKANE M.R. & DONELSON J.E. (1989). Detection of *Trypanosoma congolense* and *Trypanosoma brucei* subspecies by DNA amplification using the polymerase chain reaction. *Parasitology*, **99**, 57–66.

NGAIRA J.M., OLEMBO N.K., NJAGI E.N. & NGERANWA J.J. (2005).The detection of non-RoTat 1.2 *Trypanosoma evansi. Exp. Parasitol.*, **110**, 30–38.

NJIRU Z.K., CONSTANTINE C.C., NDUNG'U J.M., ROBERTSON I., OKAYE S., THOMPSON R.C. & REID S.M. (2004). Detection of *Trypanosoma evansi* in camels using PCR and CATT/*T. evansi* tests in Kenya. *Vet. Parasitol.*, **124**, 187–199.

OMANWAR S., RAO J.R., BASAGOUDANAVAR S.H., SINGH R.K. & BUTCHAIA G. (1999). A simple and highly sensitive method to detect *Trypanosoma evansi* by DNA amplification from crude blood samples collected on filter papers. *J. Vet. Parasitol.*, **13**, 27–29.

ONAH D.N., HOPKINS J.A. & LUCKINS A.G. (1998). Increase in CD5[+] B cells and depression of immune responses in sheep infected with *Trypanosoma evansi. Vet. Immunol. Immunopathol.*, **63**, 209–222.

PANYIM S., VISESHAKUL N., LUXANANIL P., WUYTS N. & CHOKESAJJAWATEE N. (1993). A PCR method for highly sensitive detection of *Trypanosoma evansi* in blood samples. Proceedings of EEC contractants workshops, Resistance or tolerance of animals to diseases and veterinary epidemiology and diagnostic methods, Rethymno, Greece, 2–6 November 1992. CIRAD-EMVT, Maisons Alfort, France (Monographie), 138–143.

PAYNE R.C., SUKANTO I.P., DJAUHARI D., PARTOUTOMO S., WILSON A.J., JONES T.W., BOID R. & LUCKINS A.G. (1991). *Trypanosoma evansi* infection in cattle, buffaloes and horses in Indonesia. *Vet. Parasitol.*, **38**, 109–119.

PENCHENIER L., DUMAS V., GREBAUT P., REIFENBERG J.-M. & CUNY G. (1996). Improvement of blood and fly gut processing for PCR diagnosis of trypanosomosis. *Parasite*, **4**, 387–389.

RAE P.F., THRUSFIELD M.V., HIGGINS A., AITKEN C.G.G., JONES T.W. & LUCKINS A.G. (1989). Evaluation of enzyme immunoassays in the diagnosis of camel (*Camelus dromedarius*) trypanosomiasis: a preliminary investigation. *Epidemiol. Infect.*, **102**, 297–307.

REID S.A. & COPEMAN D.B. (2002). Evaluation of an antibody–ELISA using five crude antigen preparations for the diagnosis of *Trypansoma evansi* infection in cattle. *Vet. Parasitol.*, **104**, 79–84.

REID S.A. & COPEMAN D.B. (2003). The development and validation of an antibody–ELISA to detect *Trypanosoma evansi* infection in cattle in Australia and Papua New Guinea. *Prev. Vet. Med.*, **61**, 195–208.

REID S.A., HUSEIN A. & COPEMAN D.B. (2001). Evaluation and improvement of parasitological tests for *Trypanosoma evansi* infection. *Vet. Parasitol.*, **102**, 291–297.

SACHS R. (1984). Improvements in the miniature anion exchange centrifugation technique for detecting trypanosomes in domestic pigs. *Trans. R. Soc. Trop. Med. Hyg.,* **78**, 561.

SOLANO P., MICHEL J.F., LEFRANÇOIS T., DE LA ROCQUE S., SIDIBE I., ZOUNGRANA A. & CUISANCE D. (1999). Polymerase chain reaction as a diagnosis tool for detecting trypanosomes in naturally infected cattle in Burkina Faso. *Vet. Parasitol.*, **86**, 95–103.

TAYLOR T.K., BOYLE D.B. & BINGHAM J. (2008). Development of a TaqMan PCR assay for the detection of *Trypanosoma evansi*, the agent of surra. *Vet. Parasitol.*, **153**, 255–264.

THEKISOE O.M., INOUE N., KUBOKI N., TUNTASUVAN D., BUNNOY W., BORISUTSUWAN S., IGARASHI I. & SUGIMOTO C. (2005). Evaluation of loop-mediated isothermal amplification (LAMP), PCR and parasitological tests for detection of *Trypanosoma evansi* in experimentally infected pigs. *Vet. Parasitol.,* **130**, 327–330.

TRAN T., CLAES F., VERLOO D., DE GREEVE H. & BUSCHER P. (2009). Towards a new reference test for surra in camels. *Clin. Vaccine Immunol.,* **16**, 999–1002.

TUNTASUVAN D., CHOMPOOCHAN T., VONGPAKORN M. & MOHKAEW K. (1996). Detection of *Trypanosoma evansi* antibodies in pigs using an enzyme linked immunosorbent assay*. J. Thai Vet. Med. Assoc.,* **47***,* 45–53.

UILENBERG G. (1998).A field guide for the diagnosis treatment and prevention of African animal trypanosomosis. FAO, Rome, Italy, 158 p.

VAN MEIRVENNE N., MAGNUS E. & BUSCHER P. (1995). Evaluation of variant specific trypanolysis tests for serodiagnosis of human infections with *Trypanosoma brucei gambiense. Acta Trop.*, **60**, 189–199.

VENTURA R.M., TAKEDA G.F., SILVA R.A., NUNES V.L., BUCK G.A. & TEIXEIRA M.M. (2002). Genetic relatedness among *Trypanosoma evansi* stocks by random amplification of polymorphic DNA and evaluation of a synapomorphic DNA fragment for species-specific diagnosis. *Int. J. Parasitol.*, **32**, 53–63.

VERLOO D., HOLLAND W., MY L.N., THANH N.G., TAM P.T., GODDEERIS B., VERCRUYSSE J. & BUSCHER P. (2000). Comparison of serological tests for *Trypanosoma evansi* natural infections in water buffaloes from north Vietnam. *Vet. Parasitol.,* **92**, 87–96.

VERLOO D., MAGNUS E. & BUSCHER P. (2001). General expression of RoTat 1.2 variable antigen type in *Trypanosoma evansi* isolates from different origin. *Vet. Parasitol.*, **97**, 183–189.

VERLOO D., TIBAYRENC R., MAGNUS E., BÜSCHER P. & VAN MEIRVENNE N. (1998). Performance of serological tests for *Trypanosoma evansi* infections in camels from Niger. *J. Protozool. Res.*, **8**, 190–193.

VISESHAKUL N. & PANYIM S. (1990). Specific DNA probe for the sensitive detection of *Trypanosoma evansi*. *Southeast Asian J. Trop. Med. Public Health,* **21**, 21–27.

WARBURG O. & CHRISTIAN W. (1942). Isolation and crystallization of enolase. *Biochem. Z.,* **310**, 384–421.

WUYTS N., CHODESAJJAWATEE N. & PANYIM S. (1994). A simplified and highly sensitive detection of *Trypanosoma evansi* by DNA amplification. *Southeast Asian J. Trop. Med. Public Health,* **25**, 266–271.

WUYTS N., CHOKESAJJAWATEE N., SARATAPHAN N. & PANYIM S. (1995). PCR amplification of crude blood on microscope slides in the diagnosis of *Trypanosoma evansi* in dairy cattle. *Ann. Soc. Belge Med. Trop.*, **75**, 229–237.

ZABLOTSKIJ V.T., GEORGIU C., DE WAAL T., CLAUSEN P.H., CLAES F. & TOURATIER L. (2003). The current challenges of dourine: difficulties in differentiating *Trypanosoma equiperdum* within the subgenus Trypanozoon. *Rev. Sci. Tech.*, **22**, 1087–1096.

*

* *

NB: There are OIE Reference Laboratories for *Trypanosoma evansi* infection (surra)
(see Table in Part 4 of this *Terrestrial Manual* or consult the OIE Web site for the most up-to-date list:
http://www.oie.int/en/scientific-expertise/reference-laboratories/list-of-laboratories/).
Please contact the OIE Reference Laboratories for any further information on
diagnostic tests and reagents for surra

NB: FIRST ADOPTED IN 1991 AS SURRA (*T. EVANSI*); MOST RECENT UPDATES ADOPTED IN 2012.